Skip to main
HALO
HALO logo

Halozyme Therapeutics (HALO) Stock Forecast & Price Target

Halozyme Therapeutics (HALO) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 30%
Buy 22%
Hold 39%
Sell 9%
Strong Sell 0%

Bulls say

Halozyme Therapeutics Inc is projected to experience revenue growth primarily driven by increased royalty revenues, with a forecasted 23% year-over-year growth in revenues for the first quarter of 2025, amounting to $240 million. The company's strong performance in the fourth quarter was significantly supported by a notable increase in prescription and royalty revenue from partnered products like Darzalex, Phesgo, and Vyvgart Hytrulo, underscoring a robust market demand for its coformulated solutions. Furthermore, ongoing business development efforts aimed at securing new partnership agreements and advancements in clinical programs are expected to yield additional positive catalysts that could enhance the company's market position and financial prospects.

Bears say

Halozyme Therapeutics is facing a challenging financial outlook, highlighted by a projected ~10% decrease in royalties for 1Q25, with historically low first-quarter financials expected to persist due to the timing of product launches and milestone payments. Compounding this concern, Merck's potential strategy to circumvent Halozyme's patents for a subcutaneous version of KEYTRUDA could significantly impact revenue, especially as key patents are set to expire in 2028, increasing competition from biosimilars. Additionally, the company grapples with multiple risks, including commercial uncertainties regarding its flagship product ENHANZE, potential setbacks in clinical data, and partnership vulnerabilities that may lead to long-term dilution for shareholders.

Halozyme Therapeutics (HALO) has been analyzed by 23 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 22% recommend Buy, 39% suggest Holding, 9% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Halozyme Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Halozyme Therapeutics (HALO) Forecast

Analysts have given Halozyme Therapeutics (HALO) a Buy based on their latest research and market trends.

According to 23 analysts, Halozyme Therapeutics (HALO) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Halozyme Therapeutics (HALO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.